Introduction & Epidemiology
Carcinoma of the breast is the most common malignancy in women globally and the leading cause of cancer-related mortality in Indian women.
Global Burden
WHO / GLOBOCAN 2022
- 2.3 million new cases annually (most common cancer globally)
- 685,000 deaths per year worldwide
- 1 in 8 women lifetime risk (Western populations)
- Incidence rising in Asia and developing nations
Indian Epidemiology
ICMR / NCG Data 2023
- ~178,000 new cases/year; #1 cancer in Indian women
- Younger age at presentation (45–50 yrs vs 60–65 in West)
- ~70% present in Stage III–IV (late-stage at diagnosis)
- Age-standardized rate: 25.8 per 100,000
- Urban > Rural incidence (changing rapidly)
Risk Factors
Non-modifiable Risk Factors
- Female sex (female:male = 100:1)
- Age (risk ↑ after 40; peak 50–64 yrs)
- Family history (1st-degree relative: 2× risk; 2 relatives: 3–4×)
- BRCA1/2 mutations (50–85% lifetime risk)
- Menarche <12 years; menopause >55 years
- Nulliparity or first childbirth >30 years
- Dense breast tissue (BI-RADS D)
- Prior breast biopsy showing atypical hyperplasia
- Chest wall radiation in youth (e.g., Hodgkin lymphoma)
- LCIS (Lobular Carcinoma In Situ) — marker lesion
Modifiable Risk Factors
- Postmenopausal obesity / high BMI
- Alcohol consumption (dose-dependent: 7–10% ↑/drink/day)
- Exogenous hormone use (OCP: slight ↑; HRT: ↑ especially combined)
- Sedentary lifestyle (physical activity ↓ risk by 25–30%)
- Tobacco smoking (modest association)
- Reproductive factors — no breastfeeding (protective if breastfed)
- Diet: Western diet (high fat, processed food) — association
- Night shift work (melatonin disruption — IARC Group 2A)
Genetic Predisposition
🧬 High-Risk Gene Mutations
Genetic testing is recommended for patients meeting high-risk criteria (personal/family history criteria — NCG/NCCN guidelines).
| Gene | Lifetime Risk | Cancer Association | Testing Indication |
|---|---|---|---|
| BRCA1 | 55–85% | Breast, Ovarian, Pancreatic | Family history, TNBC, young-onset |
| BRCA2 | 45–85% | Breast (M+F), Ovarian, Prostate, Pancreatic | Male breast cancer, family history |
| PALB2 | 35–58% | Breast, Pancreatic | BRCA-negative family history |
| CHEK2 | 20–40% | Breast, Colon | Moderate-risk family history |
| ATM | 20–30% | Breast, Pancreatic | Moderate-risk family history |
| TP53 | Up to 90% | Li-Fraumeni syndrome (multiple cancers) | Early-onset, rare tumors family |
| CDH1 | 42% | Lobular breast, Gastric (diffuse) | Lobular breast cancer family |
| PTEN | 25–50% | Cowden syndrome — breast, thyroid, uterus | Macrocephaly, multiple hamartomas |
NCG India Recommendation
The National Cancer Grid India recommends genetic counseling and testing for: (1) ≤45 yrs at diagnosis; (2) Triple-negative breast cancer at any age; (3) ≥2 breast cancers in close relatives; (4) Breast + ovarian cancer in family; (5) Male breast cancer in family.
Symptoms
Clinical presentation varies by stage, subtype, and patient factors. A high index of suspicion is required for early detection.
Early Symptoms
Potentially curable stage
- Painless breast lump (most common presenting symptom)
- Breast skin changes — dimpling, puckering
- Nipple discharge (spontaneous, unilateral, blood-stained)
- Change in breast shape or size
- Nipple retraction or inversion (new onset)
- Axillary lymph node enlargement
Advanced / Late Symptoms
Locally advanced / metastatic disease
- Fungating or ulcerating breast wound
- Chest wall fixation of mass
- Peau d'orange appearance (inflammatory)
- Arm lymphedema (axillary involvement)
- Bone pain (skeletal metastasis)
- Dyspnea / pleural effusion (lung mets)
- Jaundice / hepatomegaly (liver mets)
- Headache, neurological deficit (brain mets)
- Pathological fracture
Red Flag Symptoms
🚩 Red Flags — Urgent Evaluation Required
Any of the following warrant urgent (within 2 weeks) diagnostic evaluation: (1) New breast lump in any woman over 30 or any post-menopausal woman; (2) Unilateral bloody nipple discharge; (3) Rapidly growing breast mass with skin changes; (4) Axillary lymphadenopathy with no infection; (5) Inflammatory breast changes (erythema, warmth, edema without fever); (6) New bone pain in known/suspected breast cancer patient.
Symptoms by Subtype
| Subtype / Situation | Characteristic Presentation |
|---|---|
| Inflammatory Breast Cancer (IBC) | Rapid onset erythema, warmth, edema of ≥1/3 of breast skin. Peau d'orange. No distinct lump. Often misdiagnosed as mastitis. Pitting edema, dermal lymphatic invasion. NO fever in most cases. |
| Paget's Disease | Eczematous change of nipple-areola complex. Itching, burning, redness, crust. May mimic eczema for months. Often underlying DCIS or invasive carcinoma. |
| DCIS (Stage 0) | Often asymptomatic — detected on screening mammogram (microcalcifications). May cause nipple discharge or small palpable lump. |
| Metastatic Disease | Bone: constant deep pain, worse at night. Lung: dyspnea, non-productive cough. Liver: RUQ pain, jaundice, ascites. Brain: headache (worse in morning), seizures, focal deficits. Skin: nodules in chest wall / scar area. |
| TNBC | Often aggressive, rapidly growing, young patient. May present with large lump in short duration. Higher risk of visceral and CNS metastasis. |
Clinical Signs
Systematic clinical examination using inspection, palpation, and lymph node assessment is the cornerstone of initial evaluation.
Inspection Findings
Patient Positioning
- Arms by side — resting position
- Arms raised above head — stretches Cooper's ligaments
- Hands pressed on hips — pectoral contraction
- Leaning forward — allows dependent breast inspection
What to Look For
- Asymmetry of breast contour or size
- Skin dimpling or tethering (Cooper's ligament involvement)
- Nipple deviation / retraction / inversion
- Skin discoloration (erythema in IBC)
- Peau d'orange (lymphatic obstruction)
- Ulceration or fungating lesion
- Visible dilated veins
- Chest wall asymmetry / arm edema
Palpation Findings
Technique
Palpate in systematic pattern (concentric circles or radial). Include entire breast, nipple-areolar complex, tail of Spence, and axillary tail. Palpate in supine (breast tissue spread over chest wall) and sitting positions.
| Feature | Benign Characteristics | Malignant Characteristics |
|---|---|---|
| Consistency | Soft, rubbery, smooth | Hard, gritty, stony |
| Borders | Well-defined, smooth | Irregular, ill-defined, spiculated |
| Mobility | Freely mobile in all directions | Fixed to skin or chest wall (advanced) |
| Tenderness | Often tender (fibrocystic) | Usually non-tender (painless lump) |
| Skin overlying | Normal | Dimpling, peau d'orange, ulceration |
| Nipple | Normal or discharge (milky) | Retraction, blood-stained discharge |
Lymph Node Evaluation
Axillary Assessment
- Support patient's arm to relax pectoralis → examine with fingertips
- Level I: anterior (pectoral), posterior (subscapular), lateral groups
- Level II: central group (deep to pectoralis minor)
- Level III: apical/infraclavicular (above pectoralis minor)
- Record: size, consistency, matting, fixity to chest wall/skin
- Malignant node: hard, non-tender, may be matted/fixed
Other Nodal Groups
- Supraclavicular — examine with neck flexed; involvement = N3c
- Infraclavicular — along subclavian vessels
- Internal mammary — not clinically palpable but on imaging
- Contralateral axillary / supraclavicular — metastatic disease
- Cervical nodes — advanced/metastatic disease
Skin & Nipple Changes
Peau d'Orange
Skin resembles orange peel due to cutaneous lymphatic obstruction. Skin pores become prominent. Seen in locally advanced and inflammatory breast cancer. Pathology: dermal lymphatic tumor emboli.
Nipple Retraction
New-onset retraction = malignancy until proven otherwise. Distinguish from congenital inversion (bilateral, everts manually). Caused by Cooper's ligament shortening and ductal involvement by tumor.
Ulceration
Indicates advanced local disease. T4b (AJCC). Non-healing ulcer with everted edges, foul discharge. May be complicated by secondary infection. Palliative surgery / wound care may be needed.
Signs of Metastasis
| Site | Clinical Signs | Imaging |
|---|---|---|
| Bone | Point tenderness, pathological fracture, SVCO (vertebral mets), hypercalcemia (confusion, polyuria, constipation) | Bone scan, X-ray, MRI spine, PET-CT |
| Liver | Hepatomegaly (nodular), jaundice, RUQ tenderness, ascites, palmar erythema | USG abdomen, CT liver with contrast |
| Lung | Reduced breath sounds, pleural effusion (stony dull), dyspnea, lymphangitis (bilateral crackles) | Chest X-ray, HRCT thorax |
| Brain | Papilledema, focal neurological deficit, cerebellar signs, headache (worse morning / Valsalva) | MRI brain with contrast (preferred) |
| Skin/Chest wall | Nodules in scar / skin, dermal metastases, chest wall infiltration | Clinical + biopsy if uncertain |
Screening & Early Detection
Early detection through screening significantly reduces breast cancer mortality. Recommendations vary by risk status and national guidelines.
Population-Based Screening Recommendations
| Organization | Age to Start | Frequency | Modality |
|---|---|---|---|
| NCCN 2025 NCCN | 40 years (average risk) | Annual | Digital mammography or DBT (tomosynthesis) |
| ASCO 2024 ASCO | 40 years | Annual until 55, then biennial if preferred | Mammography; DBT preferred where available |
| ESMO 2024 ESMO | 50 years (average risk); 40–49 shared decision | Every 2 years | Mammography; consider supplemental USG in dense breasts |
| NCG India 2023 NCG | 40 years (opportunistic); age 50+ (organized) | Annual or biennial | Mammography; USG (supplemental, especially dense breasts); CBE in low-resource settings |
Mammography Guidelines — Age-Wise
Age 40–49
- Annual mammography recommended (NCCN, ASCO 2024)
- Shared decision-making — discuss benefits/harms
- DBT (tomosynthesis) preferred where available
- Dense breast tissue more common → consider supplemental USG
Age 50–74
- Annual mammography (NCCN / ASCO)
- Biennial acceptable if patient prefers (ASCO, ESMO)
- Benefit clearly outweighs harm in this age group
- Organized programs target this group (NCG India)
Age ≥75
- Individualize based on life expectancy and comorbidities
- Continue if 10-yr life expectancy >10 years (NCCN)
- Frailty screening before deciding
Role of Ultrasound & MRI
Ultrasound (USG Breast)
- Adjunct to mammography (not standalone screening)
- Preferred in women <30 years (dense breast)
- Supplemental screening in dense breasts (BI-RADS C/D)
- Evaluation of palpable lump and mammographic abnormality
- Guidance for core biopsy
- Axillary lymph node evaluation
- Cannot detect microcalcifications
Breast MRI
- High sensitivity (95%), but lower specificity
- Not recommended for routine average-risk screening
- Indicated in high-risk women:
- BRCA1/2 mutation carriers
- Lifetime risk >20–25%
- Chest wall radiation before age 30
- Staging of known breast cancer (extent of disease)
- Response assessment after neoadjuvant therapy
- Dense breast + strong family history
High-Risk Screening Protocol — BRCA Carriers
High-Risk Protocol (NCG India / NCCN)
For BRCA1/2 carriers and women with >20% lifetime risk: Annual MRI + Annual mammography starting at age 25–30 (or 10 years before youngest family member's diagnosis). Clinical breast exam every 6 months. Consider risk-reduction surgery discussion.
Breast Self-Examination vs Clinical Breast Exam
Breast Self-Examination (BSE)
- No longer formally recommended as a screening tool
- Does NOT reduce mortality in RCTs
- May increase benign biopsy rates
- However: "Breast awareness" is encouraged — woman should know normal feel of her breasts and report changes promptly
- Particularly important in LMIC settings with limited screening infrastructure (NCG India)
Clinical Breast Exam (CBE)
- Part of routine well-woman examination
- Every 1–3 years for women 25–39 years (NCCN)
- Annual for women ≥40 years
- Technique: systematic palpation in supine position, all quadrants + axilla
- Can detect lesions missed by mammogram (especially palpable, non-calcified)
- Recommended by NCG India in low-resource settings as primary screening tool
Diagnostic Workup
Triple assessment (clinical + imaging + pathology) remains the gold standard. Core needle biopsy is the preferred tissue acquisition method.
The Triple Assessment Principle
Concordance of all three components determines next steps. Discordant triple assessment requires repeat or excision biopsy. Never treat based on cytology alone.
1. Clinical Examination
See "Clinical Signs" section for detailed examination technique.
2. Imaging
| Investigation | Indication | Key Finding |
|---|---|---|
| Digital Mammogram (2D) | Women ≥40 years; screening + diagnostic | Mass (spiculated), microcalcifications, distortion, asymmetry |
| Digital Breast Tomosynthesis (DBT) | Dense breasts; preferred diagnostic modality 2025 | Better detection in dense tissue; reduces recall rate |
| USG Breast | Women <40; palpable lump; cystic vs solid; biopsy guidance | Solid hypoechoic mass, angular margins, posterior shadowing |
| Breast MRI | Extent of disease; neoadjuvant response; high-risk screening | Enhancing mass; rim enhancement; satellite lesions |
| Galactography | Nipple discharge + no palpable mass | Filling defect in duct |
BI-RADS Classification
| Category | Finding | Malignancy Risk | Action |
|---|---|---|---|
| 0 | Incomplete | — | Additional imaging needed |
| 1 | Negative | ~0% | Routine screening |
| 2 | Benign | 0% | Routine screening |
| 3 | Probably benign | <2% | Short-interval follow-up (6 months) |
| 4A | Low suspicion | 2–10% | Tissue diagnosis |
| 4B | Moderate suspicion | 10–50% | Tissue diagnosis |
| 4C | High suspicion | 50–95% | Tissue diagnosis |
| 5 | Highly suggestive of malignancy | >95% | Tissue diagnosis + treatment planning |
| 6 | Biopsy-proven malignancy | — | Staging + treatment |
3. Pathology
FNAC (Fine Needle Aspiration Cytology)
- Quick, less invasive; OPD procedure
- Cytology only — no architecture, no ER/PR/HER2
- C1: Inadequate; C2: Benign; C3: Atypical; C4: Suspicious; C5: Malignant
- Sensitivity ~90%, Specificity ~99% (experienced cytopathologist)
- NOT sufficient alone for treatment planning
- Useful: cyst aspiration, lymph node evaluation
Core Needle Biopsy (CNB) — PREFERRED
- 14–16G core under USG or stereotactic guidance
- Provides histology + IHC markers
- Required for ER/PR/HER2/Ki-67 determination
- Required for treatment planning and neoadjuvant chemotherapy decisions
- Sensitivity ~97%, Specificity ~99%
- Vacuum-assisted biopsy (VAB) for microcalcifications / small lesions
Histopathology Classification
| Type | Frequency | Key Features |
|---|---|---|
| Invasive Ductal Carcinoma NOS | ~75% | Most common; NST (No Special Type); glandular/tubular structures |
| Invasive Lobular Carcinoma | ~10–15% | Single-file ("Indian file") pattern; E-cadherin negative; bilateral risk |
| Mucinous / Colloid | ~2% | Abundant mucin; favorable prognosis; often ER+ |
| Medullary | ~1–2% | High grade but better prognosis; syncytial growth; lymphocytic infiltrate |
| Tubular | <2% | Well-differentiated; excellent prognosis; small tubular structures |
| Metaplastic | <1% | Rare; ER/PR/HER2 negative; chemotherapy-resistant; aggressive |
| Inflammatory BC (IBC) | 1–5% | Clinical diagnosis; dermal lymphatic invasion on biopsy; T4d staging |
| DCIS | ~15–20% of all DX | Non-invasive; in-situ; no basement membrane penetration; Stage 0 |
Immunohistochemistry (IHC) & Molecular Subtyping
Mandatory IHC Panel (NCG India / NCCN)
ER, PR, HER2, Ki-67 — required on all newly diagnosed invasive breast cancer. HER2 ISH (FISH/CISH) if IHC 2+.
Luminal A
ER+ PR+ HER2− Ki67 <20%
- Best prognosis
- Hormone therapy driven
- Low recurrence score
- Chemotherapy often NOT needed
Luminal B
ER+ PR± HER2± Ki67 ≥20%
- Intermediate prognosis
- Hormone therapy + consider chemotherapy
- Higher proliferative index
- Oncotype DX / Mammaprint helps guide chemo decision
HER2-Enriched
ER− PR− HER2+
- Aggressive biology
- Anti-HER2 therapy essential
- Trastuzumab + pertuzumab ± chemotherapy
- Good response to targeted therapy
Triple-Negative (TNBC)
ER− PR− HER2−
- Most aggressive subtype
- Chemotherapy backbone
- Immunotherapy (pembrolizumab) in selected cases
- Test BRCA1/2 mutation (PARP inhibitors)
- Higher CNS/visceral metastasis risk
| Marker | Positivity Threshold | Clinical Significance |
|---|---|---|
| ER | ≥1% nuclear staining (ASCO/CAP 2020) | Hormone receptor positive → endocrine therapy |
| PR | ≥1% nuclear staining | Prognostic value; low PR may indicate Luminal B |
| HER2 | IHC 3+ (or FISH ratio ≥2.0) | HER2-targeted therapy; anti-HER2 agents |
| HER2-Low | IHC 1+ or 2+ with FISH negative | New category 2023; eligible for T-DXd (trastuzumab deruxtecan) |
| Ki-67 | <20% = low; ≥20% = high | Proliferative index; guides Luminal A vs B distinction |
| PD-L1 | CPS ≥10 (KEYNOTE-522 criteria) | Eligibility for pembrolizumab (TNBC, early stage) |
Staging (AJCC TNM)
8th Edition AJCC TNM staging system — incorporates anatomic + prognostic stage grouping (including ER/PR/HER2/grade/Oncotype DX score).
T — Primary Tumor
| Category | Definition |
|---|---|
| Tis | Carcinoma in situ (DCIS, Paget's with no invasive component) |
| T1 | Tumor ≤20 mm — T1mi (≤1mm), T1a (1–5mm), T1b (5–10mm), T1c (10–20mm) |
| T2 | Tumor >20 mm but ≤50 mm |
| T3 | Tumor >50 mm |
| T4a | Extension to chest wall (NOT including pectoralis muscle invasion alone) |
| T4b | Skin ulceration/ipsilateral satellite nodules / peau d'orange (not meeting T4d) |
| T4c | Both T4a and T4b |
| T4d | Inflammatory carcinoma (clinical diagnosis) |
N — Regional Lymph Nodes (Clinical)
| Category | Definition |
|---|---|
| N0 | No regional lymph node metastasis |
| N1 | Movable ipsilateral Level I/II axillary nodes |
| N2a | Fixed or matted ipsilateral Level I/II axillary nodes |
| N2b | Internal mammary nodes (clinically detected, without axillary mets) |
| N3a | Infraclavicular (Level III axillary) nodes |
| N3b | Internal mammary + ipsilateral axillary nodes |
| N3c | Ipsilateral supraclavicular lymph nodes |
M — Distant Metastasis
- M0: No distant metastasis
- M1: Distant metastasis present
- Common sites: bone (65%), lung (30%), liver (25%), brain (15%)
Imaging for Staging
- Stage I–IIA: No routine staging imaging if asymptomatic
- Stage IIB–III: CT chest/abdomen/pelvis + bone scan (NCCN)
- Stage III–IV: PET-CT preferred (if available)
- Liver: CT with contrast or MRI liver
- Brain: MRI brain (if symptomatic; routine in TNBC/HER2+ Stage IV)
Stage Grouping
Stage 0 — Carcinoma In Situ
Tis N0 M0
▾
DCIS — Ductal Carcinoma In Situ. Confined to breast duct/lobule, no invasion. Excellent prognosis (>98% 10-year survival). Management: BCS + radiation or mastectomy ± endocrine therapy. No systemic chemotherapy required.
Stage I — Early Invasive
T1 N0 M0 (IA) | T0–1 N1mi M0 (IB)
▾
Stage IA: Small tumor, node-negative. Excellent prognosis. BCS (preferred) + SLNB. Adjuvant therapy based on subtype.
Stage IB: Small tumor + micrometastasis in nodes. SLNB ± ALND. Systemic therapy as per receptor status.
Stage II — Early-Intermediate
T2 N0–1 / T0–1 N1 M0
▾
Stage IIA: T1N1 or T2N0. Surgical resection ± neoadjuvant chemotherapy. Adjuvant systemic therapy based on molecular subtype.
Stage IIB: T2N1 or T3N0. Consider neoadjuvant if large tumor or certain subtypes (TNBC, HER2+). SLNB or ALND per nodal status.
Stage III — Locally Advanced
T3N1, T0–3N2, T4anyN, anyTN3 M0
▾
Stage IIIA–C: Includes large/fixed nodes, chest wall extension, supraclavicular nodes, IBC. Neoadjuvant chemotherapy (NACT) is standard upfront approach to downstage for surgery. Multidisciplinary management essential.
Stage IV — Metastatic
Any T, Any N, M1
▾
Not curable in most cases. Goal: prolonged survival, symptom control, quality of life. Treatment based on molecular subtype, site of metastasis, and prior therapy. Median survival improving with modern systemic therapies (HR+: 3–5 years; HER2+: 4–5 years; TNBC: 12–18 months).
Management
Multimodality, multidisciplinary management guided by stage, molecular subtype, menopausal status, comorbidities, and patient preference.
Multidisciplinary Team (MDT) — Mandatory for All Cases
Medical Oncologist · Surgical Oncologist · Radiation Oncologist · Pathologist · Radiologist · Genetic Counselor · Nurse Navigator · Palliative Care (as needed). All cases should be discussed at MDT tumor board before treatment initiation.
A. Surgical Management
| Procedure | Indication | Key Points |
|---|---|---|
| Breast-Conserving Surgery (BCS) | Stage I–II; favorable tumor-breast ratio; no multicentric disease; patient preference | Margins must be clear (>2mm for DCIS; no ink on tumor for invasive). Mandatory post-op radiotherapy. Equivalent survival to mastectomy in eligible patients. |
| Modified Radical Mastectomy (MRM) | Multicentric disease; inflammatory BC; large tumor in small breast; BRCA carrier electing prophylactic; patient preference | Removes entire breast + level I/II axillary nodes. Pectoralis muscles preserved. Reconstruction can be immediate or delayed. |
| Sentinel Lymph Node Biopsy (SLNB) | Clinically node-negative (cN0); preferred over routine ALND | Blue dye ± radioisotope (Tc-99m). If SLNB negative → no further axillary surgery. If 1–2 positive SNs → may omit ALND (Z0011 criteria). If 3+ SN positive → ALND or regional nodal radiation. |
| Axillary Lymph Node Dissection (ALND) | ≥3 positive sentinel nodes; clinically positive axilla (N1–N3); post-neoadjuvant residual nodal disease | Level I/II ALND standard. Level III if bulky apical nodes. Risk of lymphedema (15–25%). Preserves long thoracic and thoracodorsal nerves. |
| Oncoplastic Surgery | Large tumor / suboptimal tumor-breast ratio where BCS would leave cosmetic defect | Combines oncological resection with plastic surgical techniques. Volume displacement or replacement. Avoids mastectomy in selected patients. |
Reconstruction Options
Implant-Based Reconstruction
- Tissue expander followed by permanent implant
- Direct-to-implant (immediate) — if adequate skin envelope
- Less donor site morbidity
- Radiation may compromise implant outcomes
Autologous Flap Reconstruction
- TRAM flap (transverse rectus abdominis myocutaneous)
- DIEP flap (deep inferior epigastric perforator) — preferred free flap
- Latissimus dorsi flap
- Better long-term results if post-mastectomy radiation planned
B. Chemotherapy
Neoadjuvant Chemotherapy (NACT)
- Downstages tumor — converts inoperable → operable; MRM → BCS
- Allows assessment of in-vivo tumor response (surrogate of prognosis)
- pCR (pathologic complete response) = excellent prognosis marker
- No difference in OS vs adjuvant chemotherapy (equivalent)
- Standard for: Stage III, inflammatory BC, TNBC (≥T2), HER2+ (≥T2 or N+)
Adjuvant Chemotherapy
- After surgery — eradicates micrometastatic disease
- Indicated: node-positive, high-grade, TNBC, HER2+, high Oncotype DX score
- Consider genomic assays (Oncotype DX, Mammaprint) in HR+ N0 to avoid overtreatment
- Start within 4–8 weeks of surgery
- Post-NACT residual disease in TNBC → capecitabine (CREATE-X trial)
Common Chemotherapy Regimens
AC-T (Anthracycline → Taxane)
AC (Doxorubicin 60mg/m² + Cyclophosphamide 600mg/m² q3w ×4) → Paclitaxel 80mg/m² weekly ×12 or Docetaxel 100mg/m² q3w ×4. Most common regimen for node-positive disease.
TC (Taxane + Cyclophosphamide)
Docetaxel 75mg/m² + Cyclophosphamide 600mg/m² q3w ×6. Used in node-negative, anthracycline-contraindicated, or lower-risk patients (CRYSTAL trial evidence).
ddAC-ddT (Dose-Dense Regimen)
AC q2w ×4 → Paclitaxel q2w ×4 with G-CSF support. Superior in node-positive disease (CALGB 9741). Reduces relative recurrence by ~15%.
TCHP (HER2-positive)
Docetaxel + Carboplatin + Trastuzumab + Pertuzumab q3w ×6 (neoadjuvant). Avoids anthracycline toxicity. TRAIN-2 trial data supports this regimen.
Pembrolizumab + Chemotherapy (TNBC Neoadjuvant)
Pembrolizumab 200mg q3w + Carboplatin + Paclitaxel ×4 cycles → Pembrolizumab + AC ×4 cycles. (KEYNOTE-522). Followed by adjuvant Pembrolizumab ×9 cycles.
C. Hormonal (Endocrine) Therapy
| Agent | Indication | Duration | Key Points |
|---|---|---|---|
| Tamoxifen | Pre- and postmenopausal ER+; DCIS | 5–10 years | SERM — blocks ER. Reduces recurrence by 50%. Side effects: DVT/PE, endometrial cancer, hot flashes. Extended therapy (10 yrs) if high-risk (ATLAS trial). |
| Aromatase Inhibitors (AI) Letrozole / Anastrozole / Exemestane | Postmenopausal ER+ | 5–10 years | Reduces circulating estrogen >99%. Superior to tamoxifen in postmenopausal women. Side effects: arthralgia, osteoporosis (monitor bone density). Letrozole preferred in most settings. |
| Ovarian Suppression (OFS) Goserelin / Leuprolide (GnRH analogues) | Premenopausal high-risk ER+ or BRCA carriers | 5 years | SOFT/TEXT trials: OFS + AI (exemestane) superior to tamoxifen alone in high-risk premenopausal women. Add to chemotherapy in high-risk young patients. |
| Fulvestrant | Metastatic ER+; AI-resistant | Until progression | Pure ER antagonist/degrader. Used with CDK4/6 inhibitors in metastatic setting. |
D. Targeted Therapy
| Drug | Target | Indication | Key Trial |
|---|---|---|---|
| Trastuzumab (Herceptin) | HER2 | HER2+ early + metastatic BC; adjuvant ×1 year | HERA, NSABP B-31 |
| Pertuzumab | HER2 dimerization | HER2+ neoadjuvant + metastatic (1st line) | CLEOPATRA, NeoSphere |
| T-DM1 (Kadcyla) | HER2 + microtubules | Residual HER2+ disease after NACT; 2nd-line metastatic HER2+ | KATHERINE, EMILIA |
| T-DXd (Enhertu) | HER2 (low and high) | HER2+ metastatic (2nd line); HER2-low metastatic | DESTINY-Breast04, -Breast03 |
| Lapatinib | HER1/HER2 TKI | HER2+ metastatic (brain mets — CNS penetration) | EGF100151 |
| Neratinib | Pan-HER TKI | Extended adjuvant HER2+ after 1yr trastuzumab | ExteNET |
| Tucatinib | HER2 TKI | HER2+ metastatic (especially brain mets) | HER2CLIMB |
| Olaparib / Talazoparib | PARP inhibitor | BRCA1/2-mutated HER2-negative metastatic + early BC | OlympiAD, EMBRACA, OlympiA |
| CDK4/6 Inhibitors Palbociclib / Ribociclib / Abemaciclib | CDK4/6 | HR+/HER2− metastatic BC (1st/2nd line); Abemaciclib in high-risk early BC | PALOMA-2, MONALEESA-7, MonarchE |
| Everolimus | mTOR inhibitor | HR+/HER2− metastatic BC; AI-resistant (with exemestane) | BOLERO-2 |
| Alpelisib | PI3K inhibitor | PIK3CA-mutated HR+/HER2− metastatic (after AI failure) | SOLAR-1 |
| Sacituzumab govitecan | TROP-2 ADC | Metastatic TNBC (≥2 prior lines); HR+/HER2− metastatic | ASCENT, TROPiCS-02 |
E. Immunotherapy
KEYNOTE-522 | FDA Approved 2021 | NCCN Category 1
Pembrolizumab in Early TNBC
Neoadjuvant: Pembrolizumab + chemotherapy (carboplatin/paclitaxel ×4 → AC ×4). Adjuvant: Pembrolizumab ×9 cycles regardless of pCR status. Improved EFS (HR 0.63 in PD-L1 CPS ≥10; benefit regardless of CPS in trial). Patient selection: All early-stage TNBC (T2+ or N+). PD-L1 testing recommended but not mandatory for eligibility per NCCN 2025.
IMpassion130 | Atezolizumab | Metastatic TNBC
Atezolizumab in Metastatic TNBC
Atezolizumab + nab-paclitaxel in PD-L1+ (IC ≥1%) metastatic TNBC. Improved PFS in PD-L1+ subset. Note: FDA approval withdrawn (2021) for nab-paclitaxel combination. Pembrolizumab + chemotherapy remains current preferred option (KEYNOTE-355) with CPS ≥10.
F. Radiation Therapy
| Indication | Target | Schedule |
|---|---|---|
| After BCS (Mandatory) | Whole breast ± boost to tumor bed | Hypofractionation: 40Gy/15fr (UK START) or 26Gy/5fr (FAST-Forward, 2020) — now standard. Conventional: 50Gy/25fr (less preferred) |
| Post-mastectomy RT (PMRT) | Chest wall ± regional nodes | Indicated: ≥4 positive nodes, T3/T4, close/positive margins, ≥1 node if high-risk features |
| Regional Nodal Irradiation (RNI) | Axilla, supraclavicular, internal mammary nodes | Individualized. Indicated if high nodal burden (MA.20, EORTC 22922 trials) |
| Partial Breast Irradiation (APBI) | Tumor bed only | Selected low-risk early BC (>50yrs, small T1 tumor, ER+, margins clear). Reduces treatment to 1–2 weeks. |
| Palliative RT | Bone mets, brain mets, symptomatic lesions | 8Gy/1fr or 20Gy/5fr (bone). WBRT or SRS for brain mets (SRS preferred for 1–3 mets — NCCN). |
G. Management by Stage Summary
| Stage | Primary Surgery | Systemic Therapy | Radiation |
|---|---|---|---|
| 0 (DCIS) | BCS or mastectomy | Tamoxifen ×5 yrs (if ER+, BCS) | WBRT after BCS; not needed after mastectomy |
| I | BCS (preferred) + SLNB | Adjuvant per subtype; Oncotype DX if HR+N0 | Hypofractionated WBRT (±boost) |
| II | BCS or MRM + SLNB/ALND | Adjuvant chemo + hormone/targeted per subtype | Post-BCS (mandatory); PMRT if high risk |
| III (LABC) | NACT first → surgery (BCS or MRM) | Full systemic treatment per subtype; escalation if no pCR | Post-mastectomy RT mandatory; post-BCS RT |
| IV (Metastatic) | Surgery rarely (palliative / primary tumor control) | Systemic therapy per subtype; CDK4/6i + ET for HR+; anti-HER2 for HER2+; chemo ± immunotherapy for TNBC | Palliative RT for symptomatic sites |
H. Management by Molecular Subtype
| Subtype | Early Disease | Locally Advanced | Metastatic |
|---|---|---|---|
| HR+/HER2− (Luminal A) | Surgery + Hormonal therapy. Omit chemo if Oncotype DX RS <16. OFS + AI in young high-risk. | NACT (AC-T) if needed. Hormonal therapy ×5–10 yrs. Consider abemaciclib (MonarchE criteria: ≥4 nodes or 1–3 nodes + high grade). | CDK4/6i (palbociclib/ribociclib/abemaciclib) + AI (1st line). Fulvestrant ± CDK4/6i (2nd line). Alpelisib + fulvestrant (PIK3CA mut). Sacituzumab govitecan (≥2 lines). |
| HR+/HER2− (Luminal B) | Chemo + hormone therapy. Higher Ki-67 → more chemo indication. Oncotype DX RS 16–25: consider chemo in premenopausal. | NACT often needed. OFS + ET in young patients. | As Luminal A + earlier chemo consideration. |
| HER2+ (HR− or HR+) | TCHP or AC-T+HP neoadjuvant. Surgery. If pCR → adjuvant trastuzumab ×1yr. If residual → T-DM1 ×14 cycles (KATHERINE). Neratinib extended adjuvant. | Dual anti-HER2 (trastuzumab + pertuzumab) + chemo NACT standard. | 1st line: Trastuzumab + pertuzumab + taxane. 2nd line: T-DXd (Enhertu). 3rd line: T-DM1 or tucatinib + capecitabine ± trastuzumab. Lapatinib for CNS mets. |
| TNBC | Pembrolizumab + chemo neoadjuvant → adjuvant pembrolizumab ×9 (if stage II+). If BRCA mut: olaparib adjuvant ×1yr (OlympiA). | NACT: pembrolizumab + carboplatin/paclitaxel → AC. If no pCR → capecitabine (CREATE-X). | PD-L1 CPS ≥10: pembrolizumab + chemo. BRCA mut: olaparib or talazoparib. Sacituzumab govitecan (TROP-2 ADC) ≥2 lines. Conventional chemo: capecitabine, gemcitabine/carboplatin, eribulin. |
Interactive Decision Support Tool
Input patient parameters to receive guideline-based management recommendations. For clinical decision support only — consult MDT for final treatment planning.
Breast Cancer Management Advisor
NCCN 2025 · ASCO 2024 · ESMO 2024 · NCG India Guidelines
Latest Updates 2024–2025
Critical recent advances that change clinical practice. All recommendations based on published trials and updated NCCN/ASCO/ESMO guidelines.
★ PRACTICE-CHANGING · KEYNOTE-522 · NCCN Category 1 2025
Immunotherapy in Early TNBC — Pembrolizumab
Pembrolizumab added to neoadjuvant chemotherapy (carboplatin/paclitaxel → AC) and continued as adjuvant therapy for 9 cycles significantly improves event-free survival (EFS) and pCR in stage II–III TNBC. 5-year EFS: 81.3% vs 72.3% (placebo). Now NCCN Category 1. PD-L1 testing recommended but benefit seen regardless of CPS status.
★ NEW INDICATION · OlympiA TRIAL · 2024 UPDATE
Expanded PARP Inhibitors in Early Breast Cancer
Olaparib adjuvant ×1 year significantly improves disease-free survival (DFS) and overall survival in germline BRCA1/2-mutated, HER2-negative high-risk early BC (T2+ or N1+ for TNBC; node-positive for HR+). 4-year OS benefit: 87.5% vs 83.2%. This is now standard of care. Talazoparib under investigation in similar setting.
★ LANDMARK · DESTINY-BREAST04 · 2023–2024
T-DXd (Trastuzumab Deruxtecan) in HER2-Low Breast Cancer
Trastuzumab deruxtecan (T-DXd / Enhertu) demonstrated superior PFS and OS vs physician's choice chemotherapy in HER2-low (IHC 1+ or 2+/FISH−) metastatic BC. This created a new HER2-low category that applies to ~60% of metastatic BC patients. Now NCCN Category 1 for HER2-low after 1 prior line. DESTINY-Breast06 (2024): benefit extended to HER2-ultralow (IHC faint).
MONARCHE TRIAL · ABEMACICLIB ADJUVANT · 2024 UPDATE
CDK4/6 Inhibitors in High-Risk Early HR+ Breast Cancer
Abemaciclib adjuvant ×2 years + endocrine therapy significantly improves IDFS in HR+/HER2− early BC with ≥4 positive nodes OR 1–3 nodes + high grade (Grade 3 or Ki-67 ≥20%). 4-year IDFS: 85.8% vs 79.4%. OS benefit confirmed in 2023 update. CDK4/6i now standard in eligible high-risk early BC. Ribociclib (NATALEE trial) also added to early BC guidelines in 2024.
FAST-FORWARD TRIAL · RADIATION · STANDARD 2025
Ultra-Hypofractionated Radiotherapy (5 Fractions)
FAST-Forward trial: 26Gy in 5 fractions over 1 week (vs 40Gy/15fr over 3 weeks) showed non-inferior local cancer control with acceptable late toxicity profile. This 1-week schedule is now endorsed by NCCN and ESMO 2024 for whole-breast irradiation after BCS. Significantly reduces treatment burden and hospital visits.
NATALEE TRIAL · RIBOCICLIB · 2024
Ribociclib in Early Breast Cancer (All Risk Groups)
Ribociclib + endocrine therapy ×3 years improves IDFS in Stage II–III HR+/HER2− early BC (including node-negative high-risk patients — unlike abemaciclib). Significant iDFS benefit at 34 months. Now NCCN-listed as an option in early BC alongside abemaciclib.
LIQUID BIOPSY · EMERGING TECHNOLOGY
Circulating Tumor DNA (ctDNA) — MRD Detection
Molecular residual disease (MRD) detection via liquid biopsy (circulating tumor DNA) is emerging as a predictive biomarker for relapse in early breast cancer. ctDNA positivity post-surgery predicts recurrence (HR 20× in some cohorts). Multiple trials ongoing (DARE, ATENEO). Not yet standard of care but anticipated to guide adjuvant therapy intensification/de-escalation in 2026+.
ESCALATION / DE-ESCALATION STRATEGIES 2024–25
Precision Therapy Approaches in Early BC
De-escalation: Oncotype DX RS <11 in postmenopausal N0 → omit chemotherapy (TAILORx). RS <16 in most patients → endocrine therapy alone. TCHP (anthracycline-free regimen) for HER2+ neoadjuvant (TRAIN-2). Omission of axillary dissection if 1–2 positive SLNB with BCS + RT (Z0011). Escalation: T-DM1 for HER2+ residual disease. Olaparib for BRCA-mutated residual/high-risk disease. Pembrolizumab for TNBC. Abemaciclib/ribociclib for high-risk HR+.
HER2CLIMB-02 · TUCATINIB · 2024
Tucatinib Combinations in HER2+ Metastatic BC
Tucatinib + T-DM1 showed improved PFS vs T-DM1 alone in HER2+ metastatic BC (HER2CLIMB-02). Tucatinib particularly relevant for patients with brain metastases due to excellent CNS penetration. Tucatinib + trastuzumab + capecitabine remains standard for 3rd-line HER2+ with brain mets (HER2CLIMB original trial).
PIK3CA / ESR1 MUTATIONS · BIOMARKER-DRIVEN THERAPY
Precision Oncology in HR+ Metastatic BC
PIK3CA mutation: Alpelisib (PI3Kα inhibitor) + fulvestrant approved for PIK3CA-mutated HR+/HER2− metastatic BC (SOLAR-1). Capivasertib (AKT inhibitor) + fulvestrant for PIK3CA/AKT1/PTEN-altered HR+ mBC (CAPItello-291 trial — 2024 approval). ESR1 mutation: Elacestrant (oral SERD) approved for ESR1-mutated HR+/HER2− mBC after CDK4/6i (EMERALD trial). Biomarker testing (ctDNA/NGS) increasingly important.
Follow-up & Surveillance
Structured follow-up to detect recurrence early, manage long-term side effects, and provide survivorship support.
Follow-up Schedule
| Time Period | Frequency | What to Assess |
|---|---|---|
| Year 1–2 | Every 3–6 months | History + clinical examination; breast awareness; treatment-related side effects |
| Year 3–5 | Every 6 months | History + clinical examination; annual mammogram (treated/contralateral breast) |
| Year >5 | Annually | History + clinical examination; annual mammogram lifelong |
Important: Routine Scans NOT Recommended for Asymptomatic Surveillance
NCCN/ASCO/NCG India do NOT recommend routine CT, bone scan, PET-CT, or tumor markers (CA 15-3, CEA) for asymptomatic surveillance. These tests do NOT improve survival and cause anxiety/over-investigation. Order only if symptoms or examination findings suggest recurrence.
Annual Surveillance Tests
All Breast Cancer Survivors
- Annual mammogram (bilateral if BCS; contralateral if MRM)
- Annual gynecological exam (especially on tamoxifen)
- Bone density (DEXA) — baseline + every 1–2 yrs on AI or OFS
- Cardiovascular assessment — especially if received anthracyclines/trastuzumab
- Lipid profile — on AI (can worsen lipids)
Specific Situations
- MRI annually — BRCA carriers, dense breast, or contralateral breast concern
- Echo/MUGA — baseline + periodic if on trastuzumab (q3 months during treatment)
- LFTs, CBC — during active systemic therapy
- Endometrial biopsy — only if abnormal uterine bleeding (on tamoxifen)
- Cognitive assessment — if chemotherapy-related cognitive complaint ("chemo brain")
Long-Term Complications of Treatment
| Treatment | Late/Long-term Complication | Management |
|---|---|---|
| Anthracyclines | Cardiomyopathy (dose-dependent); secondary AML (rare) | Echo monitoring; cardiology referral if LVEF drops >10% |
| Trastuzumab | Cardiotoxicity (usually reversible) | Echo q3 months during treatment; hold if LVEF <50% or drop >16% |
| Taxanes | Peripheral neuropathy, nail changes, alopecia | Dose modification; gabapentin/duloxetine for neuropathy |
| Tamoxifen | DVT/PE, endometrial cancer, hot flashes, cataract | DVT prophylaxis; annual gynecological exam; report abnormal bleeding |
| Aromatase Inhibitors | Osteoporosis, arthralgia, dyslipidemia, vaginal dryness | Calcium + Vit D; DEXA; bisphosphonates if osteoporosis; exercise |
| Axillary Surgery / RT | Lymphedema, shoulder stiffness, cording | Physiotherapy; compression sleeve; avoid needle/BP in affected arm |
| Chest wall RT | Radiation fibrosis, rib fracture, ischemic heart disease (left-side) | Breath-hold technique (DIBH) for left BC; physiotherapy |
| Ovarian Suppression | Premature menopause symptoms, bone loss, sexual dysfunction | HRT contraindicated; SSRI/SNRI for hot flashes; lubricants for dyspareunia |
Special Situations
Specific clinical scenarios requiring modified management approaches, multidisciplinary input, and individualized decision-making.
Breast Cancer in Pregnancy
Breast Cancer in Pregnancy — Key Principles
1 in 3,000 pregnancies. Most common cancer in pregnancy. Diagnosis often delayed due to physiological breast changes. Core needle biopsy safe in pregnancy. FNAC adequate if CNB not feasible. Mammogram with shielding acceptable.
- Surgery: Safe in all trimesters; preferred in 2nd trimester
- Chemotherapy: Contraindicated in 1st trimester (teratogenesis). Safe from 2nd trimester (AC regimen). Avoid weekly paclitaxel (insufficient safety data). Last chemo ≥3 weeks before delivery.
- Radiation: Contraindicated during pregnancy. Defer to postpartum.
- Endocrine therapy: Contraindicated (tamoxifen teratogenic)
- Trastuzumab: Contraindicated (oligohydramnios, fetal renal hypoplasia)
- Delivery: Aim for 37–38 weeks. Avoid premature delivery for chemotherapy
- Breastfeeding: Avoid on tamoxifen or chemotherapy; safe if off treatment
- Prognosis: Stage-for-stage, same as non-pregnant women
Male Breast Cancer
Epidemiology & Features
- <1% of all breast cancers; ~2,700 cases/year (USA)
- Median age: 67 years (older than women)
- ~15–20% are BRCA2 mutation carriers
- ER+ in 90%; HER2+ in ~10%; TNBC rare (3–5%)
- Usually presents with subareolar mass, nipple discharge, retraction
- Late diagnosis common (no screening programs)
Management
- MRM (modified radical mastectomy) — standard (small breast, central tumors)
- SLNB if cN0; ALND if cN+
- Tamoxifen ×5–10 years (standard; AI less effective without gonadal suppression)
- AI + GnRH analogue: if tamoxifen intolerant
- Systemic therapy otherwise same as women (subtype-based)
- BRCA2 mutation testing recommended in all males
Breast Cancer in Elderly (>70 years)
- Comprehensive geriatric assessment (CGA) before treatment
- Fit elderly: standard treatment as per guidelines (age alone not a reason to under-treat)
- Frail/comorbid elderly: primary endocrine therapy (tamoxifen/AI) if ER+ — surgery may be deferred in select cases
- Modified chemotherapy regimens if indicated (dose reduction, growth factors)
- SLNB preferred over ALND (reduced morbidity)
- RT: 5-fraction schedule (FAST-Forward) preferred (reduces hospital visits)
- Omission of post-BCS RT in women ≥70 with T1N0 ER+ on endocrine therapy (CALGB 9343 trial) — shared decision
Genetic Counseling & Prophylactic Surgery
| Option | Indication | Risk Reduction | Notes |
|---|---|---|---|
| Risk-Reducing Mastectomy (RRM) | BRCA1/2 carriers; TP53; ≥30% lifetime risk | ~90–95% reduction in breast cancer risk | Bilateral prophylactic mastectomy ± reconstruction. Discussed after BRCA confirmation. Consider after childbearing (age 35–40 for BRCA1, 40–45 for BRCA2). |
| Risk-Reducing Salpingo-Oophorectomy (RRSO) | BRCA1/2 carriers (postchildbearing) | ~50% breast cancer risk reduction; ~85% ovarian risk reduction | BRCA1: age 35–40; BRCA2: age 40–45. HRT (non-oral) after RRSO until age 50 in BRCA2 (does not negate breast cancer risk reduction). |
| Chemoprevention | High-risk women (Gail model ≥1.7% 5-yr risk; LCIS; atypical hyperplasia) | ~50% reduction in ER+ BC | Tamoxifen (pre/postmenopausal), Raloxifene (postmenopausal), Exemestane/Anastrozole (postmenopausal). NCCN recommends offer to high-risk women after shared decision. |
Palliative Care
Early integration of palliative care with oncological treatment improves quality of life, reduces hospitalization, and may prolong survival in metastatic breast cancer.
ASCO 2012 / NCG India: Palliative Care Integration
Concurrent palliative care should be offered to all patients with metastatic cancer from time of diagnosis. Not just end-of-life care — includes symptom management, psychosocial support, communication, and goal setting throughout the disease course.
Pain Management
| Pain Severity | Analgesic Approach (WHO Ladder) | Adjuvants |
|---|---|---|
| Mild (VAS 1–3) | Paracetamol / NSAIDs (if no contraindication) | — |
| Moderate (VAS 4–6) | Weak opioids: Tramadol / Codeine + Paracetamol | Gabapentin (neuropathic pain) |
| Severe (VAS 7–10) | Strong opioids: Morphine (oral preferred) / Fentanyl patch / Oxycodone | Dexamethasone (bone/visceral); Duloxetine (neuropathic); Bisphosphonates (bone pain) |
| Bone-specific pain | Bisphosphonates (zoledronic acid) or Denosumab ± palliative RT | RANK-L inhibitor (denosumab) superior in bone mets prevention |
Bone Metastasis Care
- Zoledronic acid 4mg IV q4 weeks or q12 weeks (after 1–2 years stable)
- Denosumab 120mg SC q4 weeks (superior to zoledronic acid; no renal dose adjustment needed)
- Calcium 1000–1500mg/day + Vitamin D 400–800 IU/day supplementation with bisphosphonates
- Monitor renal function (zoledronic acid). Dental assessment before starting (ONJ risk)
- Palliative RT: 8Gy/1 fraction (or 20Gy/5fr) for painful bone mets — excellent palliation
- Surgical stabilization for impending or actual pathological fracture (orthopedic referral)
- Vertebroplasty/kyphoplasty for vertebral compression fractures
- SRS/SBRT for oligometastatic bone disease (selected patients)
Brain Metastasis Management
- MRI brain with gadolinium for diagnosis
- Dexamethasone for cerebral edema (4–16mg/day, taper over 1–2 weeks)
- SRS (stereotactic radiosurgery): preferred for 1–3 brain mets ≤3cm (excellent local control; avoids WBRT cognitive effects)
- WBRT: for multiple (>3–4) mets, leptomeningeal disease, or poor KPS
- HER2+ brain mets: tucatinib + capecitabine + trastuzumab (HER2CLIMB — active systemic control)
- Neurosurgical resection: for single large met with mass effect
- Anti-epileptics: only if seizures occur (not prophylactic)
End-of-Life Care
- Recognize terminal phase: Karnofsky PS <40, >3 organ sites, progressive on ≥2 lines of therapy
- Goals-of-care discussion: document patient preferences (resuscitation, mechanical ventilation, artificial nutrition)
- Symptom management: dyspnea (morphine, midazolam), nausea, constipation (opioid-induced — laxatives routine), anxiety (lorazepam)
- Advance care planning: designation of surrogate, living will
- Discontinue non-essential medications and investigations
- Spiritual and psychological support (chaplaincy, counseling)
- Home-based palliative care or hospice referral — preferred by most patients
- Bereavement support for family
Summary Algorithms
Quick-reference diagnostic and treatment pathways for clinical use.
Diagnostic Algorithm — Breast Mass
1
Clinical Presentation: Breast Symptom / Palpable Mass
History (duration, change, nipple discharge, pain) + Systematic clinical examination + Lymph node assessment
↓
2
Imaging
Age <30: USG breast first → Mammogram if suspicious. Age ≥30/40: Mammogram (2D/DBT) + USG. BI-RADS 1–3: follow-up. BI-RADS 4–6: tissue diagnosis required.
↓
3
Tissue Diagnosis — Core Needle Biopsy (CNB)
USG-guided CNB (14G) preferred. Stereotactic biopsy for microcalcifications. Obtain ER/PR/HER2/Ki-67. FNAC only if CNB not feasible.
↓
4
Pathology Result
Benign → appropriate management. Atypical → excision biopsy (B3/C3). Malignant → proceed to staging and MDT discussion.
↓
5
Staging Workup
Stage I–IIA: Clinical exam + CXR/LFT if symptomatic. Stage IIB–III: CT chest/abdomen/pelvis + bone scan OR PET-CT. Stage IV: PET-CT + MRI brain (if symptomatic or HER2+/TNBC).
↓
6
MDT Tumor Board Discussion → Treatment Planning
Proceed to stage + subtype-based management algorithm.
Treatment Algorithm — Early Breast Cancer (Stage I–II)
| Subtype | Neoadjuvant | Surgery | Adjuvant Systemic | Radiation |
|---|---|---|---|---|
| HR+/HER2− Low-risk (Oncotype <16) | Usually not needed | BCS or MRM + SLNB | Endocrine therapy ×5–10 yrs. No chemotherapy. | After BCS: hypofractionated WBRT (26Gy/5fr or 40Gy/15fr) |
| HR+/HER2− High-risk (N+, Oncotype ≥26) | NACT (AC-T) if N2+ or large T3 | BCS or MRM | Chemo + ET ×5–10 yrs. Abemaciclib ×2 yrs if ≥4N+ or 1–3N+ high grade. Ribociclib (NATALEE). | WBRT ± regional nodes; PMRT if indicated |
| HER2+ | TCHP (preferred) or AC-THP ×6–8 cycles | Surgery after NACT. BCS if downstaged. | pCR → Trastuzumab ×1yr. Residual → T-DM1 ×14 cycles. Neratinib extended adjuvant. If HR+: ET. | As per breast/nodal status post-surgery |
| TNBC | Pembrolizumab + Carbo/Paclitaxel → Pembro + AC (KEYNOTE-522) | Surgery. Assess pCR. | pCR → Pembro ×9 cycles adjuvant. No pCR → Capecitabine ×6–8 cycles + Pembro ×9. If BRCA mut: Olaparib ×1yr (OlympiA). | Post-mastectomy RT if T3/T4 or ≥4 nodes. After BCS: WBRT |
Treatment Algorithm — Metastatic Breast Cancer
| Subtype | 1st Line | 2nd Line | 3rd Line+ |
|---|---|---|---|
| HR+/HER2− | CDK4/6i (palbociclib/ribociclib/abemaciclib) + AI (letrozole). Premenopausal: add OFS. | CDK4/6i + fulvestrant OR fulvestrant alone. Elacestrant (ESR1 mut). Alpelisib + fulvestrant (PIK3CA mut). | Sacituzumab govitecan (TROP-2 ADC). Everolimus + exemestane. Capivasertib + fulvestrant. Chemotherapy. |
| HER2+ | Trastuzumab + pertuzumab + docetaxel/paclitaxel (CLEOPATRA). If HR+: add ET after chemo. | T-DXd (trastuzumab deruxtecan / Enhertu) — DESTINY-Breast03. | Tucatinib + capecitabine + trastuzumab (esp. brain mets). T-DM1. Lapatinib-based regimens. |
| HER2-Low | As per HR status (HR+ → CDK4/6i). | T-DXd (trastuzumab deruxtecan) — DESTINY-Breast04 (Category 1). | Sacituzumab govitecan. Chemotherapy. |
| TNBC PD-L1+ (CPS ≥10) | Pembrolizumab + chemo (KEYNOTE-355). Carboplatin + gemcitabine or nab-paclitaxel. | Sacituzumab govitecan (TROP-2 ADC). If BRCA mut: olaparib/talazoparib. | Eribulin. Capecitabine. Clinical trial. Platinum if BRCA mut. |
| TNBC PD-L1 negative / BRCA mutated | BRCA mut: Olaparib or talazoparib. Chemotherapy. | Sacituzumab govitecan. | Eribulin. Vinorelbine. Clinical trial. |
Key Guiding Principles — Summary
All breast cancer patients should be discussed at MDT. Receptor status (ER/PR/HER2/Ki-67) must be known before systemic treatment. BRCA testing recommended for all TNBC and high-risk HR+ patients. Genomic assays (Oncotype DX, Mammaprint) guide chemotherapy decisions in early HR+ disease. pCR after NACT guides adjuvant therapy escalation/de-escalation. PD-L1 and PIK3CA testing important for metastatic disease treatment selection. Liquid biopsy (ctDNA/ESR1 mutation) increasingly important for treatment monitoring.